XILAGESIC 20 ml
XILAGESIC® is indicated to be used in cats and dogs as a sedative and pre-anesthetic, alone or in combination with other products.
Its use as a sedative is very useful in minor diagnostic or surgical procedures (wound healing, treatments, etc.), as well as in animal management.
Product Description
SPECIES
Pre-anesthetic sedative
COMPOSITION
Each 1 mL of solution for injection contains:
Xylazine Hydrochloride ………………………. 23.3 mg
(Equivalent to 20 mg of Xylazine base)
Excipients q.s. ……………………………………… 1 mL
INDICATIONS
XILAGESIC® is indicated to be used in cats and dogs as a sedative and pre-anesthetic, alone or in combination with other products.
Its use as a sedative is very useful in minor diagnostic or surgical procedures (wound healing, treatments, etc.), as well as in animal management.
ROUTE OD ADMINISTRATION AND DOSAGE
How to use:
In dogs, intravenous administration should be done slowly. The onset of sedative effects in dogs and cats occurs approximately 10 to 15 minutes after intramuscular or subcutaneous administration, lasting for 1 to 2 hours, depending on the dose used.
Dose of the active substance:
As a sedative | As a pre-anesthetic (in association with other injectable or inhalation anesthetics) | |
Dogs | 1.1 mg / kg intravenously, or 1.1 to 2.2 mg / kg subcutaneously or intramuscularly as a single dose | 0.5 to 1.1 mg / kg intramuscularly as a single dose |
Cats | 1.1-2.2 mg / kg subcutaneously or intramuscularly as a single dose | 1.1 to 2.2 mg / kg single dose intramuscularly |
Product dosage:
As a sedative | As a pre-anesthetic (in association with other injectable or inhalation anesthetics) | |
Dogs | Administer 0.055 mL / kg slowly intravenously, or 0.055 to 0.11 mL / kg subcutaneously or intramuscularly as a single dose | Administer 0.025 to 0.055 mL / kg intramuscularly in a single dose |
Cats | Administer 0.055 to 0.11 mL / kg subcutaneously or intramuscularly as a single dose | Administer 0.055 to 0.11 mL / kg intramuscularly as a single dose |
DRUG INTERACTIONS
- The use of Epinephrine with or without the use of Halothane concomitant with Xylazine may induce the development of ventricular arrhythmias.
- The combination of Acepromazine with Xylazine is generally considered safe, but there is the possibility of additive hypotensive effects and this combination should be used with caution in patients susceptible to hemodynamic complications.
- Other CNS depressants (barbiturates, narcotics, anesthetics, phenothiazines, etc.) can cause additive central nervous depression when used with Xylazine. The dose of these agents may need to be reduced.
CONTRAINDICATIONS
- Do not administer to cats and dogs receiving epinephrine or who have active ventricular arrhythmias.
- Do not administer during pregnancy, except at the time of delivery.
- Due to the emetic effect of xylazine, its use is contraindicated in complications of the gastrointestinal tract such as torsion of the stomach, hernia, or suspected esophageal obstruction.
- Do not use in lactation or in breeding animals.
SPECIAL PRECAUTIONS FOR USE
Special warnings and precautions for use:
- In general, emesis is observed within 3-5 minutes after administration in cats and sporadically in dogs. To prevent aspiration, do not induce additional anesthesia until this period has elapsed.
- It should be used with extreme caution in animals with pre-existing cardiac dysfunction, hypotension or shock, hypovolaemia, respiratory dysfunction, severe liver or kidney failure, pre-existing seizure disturbances, mechanical obstruction of the gastrointestinal tract, obstruction of the urinary tract, eye diseases where an increase in intraocular pressure would be harmful, and marked weakness.
- Decreased intestinal mobility leads to gas accumulation in the gastrointestinal tract, which could make radiological diagnosis difficult.
- Dog breeds such as Basset Hound, Great Dane and Irish Setter appear to be more susceptible to bloating or swelling, and may require treatment for this effect following xylazine administration.
- Due to the emetic effect of xylazine, keep animals fasted as much as possible before administration of the product.
- Avoid sensory stimulation while the effect of the drug is produced, since there may be loss of the sedative effect.
- The product should not be used in pregnant females, except at the time of delivery. Xylazine can cause premature abortion in pregnant females.
- Keep out of the reach of children.
SPECIAL PRECAUTIONS FOR THE OPERATOR
- Wash hands after administering the product.
- During product handling, do not eat, drink liquids, or smoke.
- Avoid contact with skin and eyes. In the case of contact with the eyes, it is recommended to wash with plenty of water for 15 minutes.
- In case of accidental ingestion, call a doctor or a toxicology information center. Do not induce vomiting.
- In case of accidental self-injection, consult a doctor immediately.
ADVERSE EFFECTS
Adverse effects and adverse reactions:
Vomiting or emesis may develop (1-5 minutes post administration), hypotension, muscle tremors, bradycardia, second-degree heart block, reduced respiratory rate, movement in response to acute auditory stimuli, polyuria, and hyperglycemia. Dogs can experience tympanism by aerophagia. Decreased intestinal motility and increased uterine motility can also be observed. Hypothermia symptoms can occur.
OBSERVATIONS
Overdose:
In the event of an accidental overdose, marked cardiac arrhythmias, hypotension, and respiratory and central nervous system depression may occur. Additionally, seizures may occur. Α-blocker drugs are used as antidotes or agents that reverse the effects of Xylazine. Yohimbine, Atipamezole and Tolazoline can be used alone or in combination to reverse the effects or speed recovery times in animals treated with Xylazine.
Precautions for disposing of unused product or waste material:
Dispose of this product with caution with household waste. Do not dispose of containers with product residues on the ground or water courses. For expired or unused products, contact the manufacturing laboratory.
CONSERVATION
Store between 15 and 30 ° C, protected from light. Once the container is opened, use within 3 months. Discard the unused product after that period of time.
CONDITION OF SALE
Sale with Veterinary Medical prescription.
PRESENTATION
20 ml ampoule bottle
PREPARED BY
Laboratorio Drag Pharma Chile Invetec S.A.
RECORDS
Reg. SAG N° 2179